Skip to main content

Fetal Down syndrome screening models for developing countries; Part I: Performance of Maternal Serum Screening

  • The Research article to this article has been published in BMC Health Services Research 2019 19:898



To identify the performance of fetal Down syndrome (DS) screening for developing countries.


A prospective study on MSS (maternal serum screening) with complete follow-ups (n = 41,924) was conducted in 32 network hospitals in the northern part of Thailand. Various models of MSS were tested for performance.


MSS based on Caucasian reference range resulted in very high false positive rate (FPR; 13%) in our country, compared to the rate of 7.8% with our own (Thai) reference range, whereas the detection rate was comparable. As individual screening, C-S (contingent first trimester screening including PAPP-A, and free beta-hCG, classified as a) high risk [> 1:30], indicated for invasive diagnosis; b) intermediate risk [1:30–1500], indicated for STS; and c) low risk [< 1:1500], need no further tests.) was the most effective model (sensitivity 84.9%, FPR 7.7%) but nearly one-third needed the second trimester test (STS) because of intermediate results. Additionally, about one-third had their first visits in the second trimester and had no chance of FTS (first trimester screening). C-S plus STS had a sensitivity of 82.4% and FPR 8.1% whereas independent first and second trimester screening model (I-S) gave the sensitivity of 78.4% and FPR of 7.5% but was much more convenient and practical.


C-S plus STS was the most effective models while I-S model was also effective and may be better for developing countries because of its simplicity and feasibility.

Peer Review reports


Prenatal screen of Down syndrome (DS) with maternal serum screening (MSS) has been established for two decades [1], leading to a decrease in the prevalence of DS in many developed countries. However, the prevalence in countries with low-resource settings has not changed much in recent years. Soon, we will be launching the implementation of DS screening for all women as a national policy, free of charge. It is important that before such implementation, the effectiveness of the screening methods must be thoroughly evaluated. It may be different from that used in other parts of the world, as indicated by studies in developing countries. In our experiences, such published effectiveness is not reproducible in developing countries. For example, the average body size of Thai women is much smaller than that of women in the western countries, whereas the fetal size is similar. The serum biomarkers derived from the fetus are diluted in maternal blood volume of much different size, causing great difference of concentrations in maternal blood. Many studies have shown that a racial factor has an impact on serum biomarker levels, resulting in less reliable screening accuracy [2,3,4,5,6]. The MSS concentrations are significantly higher among Asian pregnant women [7,8,9], even after correction with maternal size [7, 10, 11]. Correction for ethnicity can be achieved by either using medians of serum biomarkers for specific ethnicity [7] or using ethnic factor to correct the truly measured levels in any ethnic population to equivalent levels for a Western woman [12]. For example, ethnic factor of b-hCG level for Asian women is 0.84, used to multiply by the true measured levels before calculation for MoMs and interpretation based on the western reference ranges. Certainly, the former method is preferred. Ethnic factors for correction used in most machines are not accurate when used in other geographical areas. For instance, among Thai women, false positive rate of serum screen corrected with ethnic factor is as high as approximately 12% [13], instead of 5% as most commonly recommended. Such a high false positive rate leads to a great number of invasive diagnoses, exceeding our capability of chromosome investigations, thus precluding universal screening as a national policy. Therefore, the more proper strategy needs to be developed. This study did not include the techniques that are not practicable in low resource settings, such as NT (nuchal translucency), which needs expertise and is not widely available; integrated MSS test, which needs two screenings and the costs are double. The purpose of this study is to determine the performance of various models of MSS among Thai pregnant women representing those in developing countries.


A study of prospective screening / diagnostic test was conducted with ethical approval by the institutional review board and the women were recruited with written informed consent. The hospital network was developed in the northern part of Thailand, including 33 community hospitals, together with development of the counseling teams, ultrasound standardization for gestational age, maternal blood sampling/collection and logistic system. The study population comprised women attending antenatal care at the network hospitals between September, 2011 and May, 2016. The inclusion criteria were 1) Thai ethnicity, 2) singleton pregnancy, and 3) attending antenatal care clinic before 20 weeks of gestation. The exclusion criteria were 1) fetal anomaly, 2) incomplete data, and 3) serum samples that were collected and transported to the laboratory for more than 24 h.

Steps in the research process

The baseline demographic data of the women were assessed and immediately recorded in the protocol form at the time of blood sample collection. The data included maternal age, parity, body weight, ethnic origin and smoking habits or medical complications. All women received pretest counseling by the counselor teams specifically trained and standardized for prenatal counseling in this project. The collected blood samples were immediately transferred to the laboratory and were centrifuged for serum separation. All serum samples were measured for biomarkers at the study center using the same laboratory (fully-automated immunoassay, using DELFIA® Xpress system; Perkin Elmer, Waltham, MA, USA) and standard assay screening kits of serum biomarkers (PAPP-A, AFP, beta-hCG, and uE3). All assays were performed in batches to eliminate inter-assay variations.

Risk determination

The risk category was based on the screening in real practice, 1) STS (second trimester screening) at 15–20 weeks for women going for their first visit in the second trimester, including AFP, free beta-hCG, and unconjugated estriol, using cut-off of 1:250 for high risk; and 2) Contingent first trimester screening (C-S) for women going for their first visit at 10–14 weeks, including PAPP-A, and free beta-hCG, classified as a) high risk (> 1:30), indicated for invasive diagnosis; b) intermediate risk (1:30–1500), indicated for STS; and c) low risk (< 1:1500), need no further tests. The high risk women were referred for invasive diagnoses (amniocentesis) at the study center. Risk determination of the screening was based on the Caucasian reference ranges (built-in). The gestational age was based on ultrasound biometry of the crown-rump length in the first trimester or biparietal diameter/head circumference in the first half of pregnancy.

Follow-up of pregnancies

All recruited women were followed-up for pregnancy complications such as abortion, preterm labor, intrauterine growth restriction, pregnancy-induced hypertension, antepartum hemorrhage, intrapartum and postpartum complications. Fetal loss related to diagnostic procedures was also evaluated for later use in cost-benefit analysis. All newborns were prospectively assessed by the neonatologists / pediatricians in the team of researchers. Neonatal chromosome study was performed only for the fetuses clinically suspected of chromosomal abnormalities after evaluation by the neonatologists. Diagnosis of fetal DS was based on chromosome studies by chorionic villous sampling, amniocentesis, or postnatal studies, while non-DS was based on chromosome studies or the conclusion by the neonatologists in cases of absence of chromosome study results.

Definition of primary screening models

In real practice, the patients were managed using the screening based on Caucasian reference ranges (CRR) as mentioned above. However, the data permitted us to re-categorize the primary screening into several models, using Thai reference ranges (TRR) [14, 15], as follows: 1) Maternal age alone: High risk if maternal age is up to 35 years or more; 2) STS (second trimester screening) alone: The risk derived from serum levels of AFP, free b-hCG and uE3; 3) FTS (first trimester screening): The risk derived from serum levels of PAPP-A and free b-hCG; 4) Contingent FTS screening (C-S): The risk derived from serum levels of PAPP-A and hCG) and categorized into three groups according to the risk as mentioned above; 5) C-S plus STS: Contingent FTS for women with first visit in the first trimester and STS alone for women with first visit in the second trimester; 6) Independent FTS and STS (I-S): FTS alone for women with first visit in the first trimester and STS alone for women with first visit in the second trimester.

Statistical analysis

The diagnostic performance (detection rate and false positive rate) was assessed for the various models mentioned above. Sample size estimation was based on previous studies [16,17,18,19], which reported that MSS had a sensitivity of ≥70% at a false positive rate of 5% for fetal DS screening among unselected pregnant women. Given a confidence level of 95% and acceptable error in diagnosis of 0.1, the project needed at least 72 fetuses with DS. The prevalence of fetal DS is about 1:600 at gestational age of 16 weeks. Therefore, the study needed a sample size of at least 43,200 tests. Statistical analysis was performed using IBM SPSS version 21.0(IBM SPSS Statistics for Windows, Released 2012. Armonk, NY: IBM Corp).


Of 45,220 eligible pregnancies, 43,216 attended antenatal care clinics and met the inclusion criteria. Of them, 41,924 women accepted MSS (C-S plus STS based on CRR) either in the first trimester contingent screening or second trimester and complete data of final outcomes as shown in Fig. 1. Of all, 5405 (12.9%) were categorized as high risk (HR), including 4997 (92.45%) undergoing amniocentesis and 408 (7.55%) doing nothing. Of all, 74 pregnancies had fetal DS, including 61 and 13 with and without prenatal detection, respectively. The prevalence of fetal DS was 0.18% or 1:567. Of non-affected cases, spontaneous fetal loss after 16 weeks was 59/36,927 (0.16%) and fetal loss rate among women undergoing amniocentesis was 33/4997 (0.66%). (Very high acceptability was observed in all steps, due to free of charge in this project).

Fig. 1

Flow chart of screening cascades: contingent FTS plus STS based on Caucasian reference ranges with ethnic (Asian) factor correction

About two-thirds of women (29,692; 70.8%) first attended antenatal care in the first trimester and had a chance of FTS and C-S whereas the remaining nearly one-third (12,232; 29.2%) had first visits in the second trimester and could undergo only STS.

Screening performance of the various models is shown in Table 1. Of note, screening (C-S plus STS) based on the CRR has the comparable detection rate when compared to that based on TRR (86.8% vs 84.9%; 76.2% vs 76.2 and 83.8% vs 82.4% for C-S, STS and C-S plus STS, respectively). However, the false positive rate was much higher with the CRR when compared to that based on TRR (13.7% vs 7.7%; 11.0% vs 9.2 and 12.9% vs 8.1% for C-S, STS and C-S plus STS, respectively).

Table 1 Summary of the primary screening performance for fetal Down syndrome

Of all screening tests using TRR, FTS had better screening performance than STS (detection rate of 79.2% vs 76.2%, and false positive rate of 6.8% vs 9.2%, respectively). Nevertheless, C-S had a significantly higher detection rate when compared with simple FTS (84.9% vs 79.2%; Chi-square test; p-value < 0.001); with slightly higher false positive rate (7.7% vs 6.8%; Chi-square test; p-value < 0.001).

Among C-S, the actual risk based on CRR was classified as low risk (LR), intermediate (IR) and high risk (HR); 18,336 (61.8%), 10,962 (36.9%) and 394 (1.3%), respectively. However, when reclassified using TRR, LR, IR and HR were: 23,314 (78.5%), 5984 (20.2%), and 394 (1.3%), respectively. Note that all cases classified as LR and HR by CRR were still classified as LR and HR by TRR but, importantly, more than one-third of IR by CRR were reclassified as LR when using TRR. Interestingly, with TRR the screening performance was much better as indicated by a marked decrease in false positive rate (13.7% vs 7.7%) while the detection rate was nearly the same. Likewise, STS based on CRR had also a significantly higher false positive rate than STS based on TRR with the same detection rate (McNemar Chi-square test; p-value < 0.001) as shown in Table 1. Age-based screening gave the lowest detection rate (29.7%) with a relatively high false positive rate (11.8%).

In summary, a) Maternal serum screening (without NT) based on CRR had a very high false positive rate when compared to that based on TRR, b) As an individual test, C-S was the most effective serum screening model (detection rate of 84.9% with false positive rate of 7.7%). c) In real practice, C-S plus STS gave the best screening performance (detection rate of 82.4% with false positive rate of 8.1%), d) Age-based screening had the lowest detection rate (29.7%) and relatively high false positive rate (11.8%).


The important insights gained from this study are: 1) CRR for maternal serum screening used in other parts of the world may probably lead to erroneously high false positive rate, resulting in excessive burden of amniocentesis and unnecessary fetal losses. 2) Theoretically, C-S was the most effective serum screening test. 3) In real practice, C-S plus STS gave the best screening performance since not all women were able to undergo FTS, nearly one-third having first visits after first trimester. Nevertheless, I-S is a more practical model in terms of patient’s convenience of first visit timing and only once screening.

Interestingly, two very unusual findings were observed in MSS using CRR: 1) very high rate of intermediate risk of FTS, more than 30% (but 20% when using Thai reference range), and 2) high false positive rate in both FTS and STS. Because of the unacceptably high false positive rate and intermediate risk rate of MSS using CRR, we strongly recommended reference ranges of its population instead of ethnic correction factor unless it has been proven to be accurate in large sample size in its own population. Importantly, the very high rate of amniocentesis secondary to false positive rate is not only associated with the great number of fetal losses but the burden of chromosome laboratories is also too problematic for the government to include DS screening in health coverage as a national policy. Finally, the performance derived from our own reference range would be better used to base cost-benefit analysis (CBA) on subsequently. Cost-benefit directly depends on the performance of the screening test, both sensitivity and specificity. The accuracy of diagnostic performance is very important for further evaluation of CBA. The sensitivity and specificity of the screening test must be based on the real practice. It directly determines the number of amniocenteses and non-invasive prenatal tests (NIPT) or cell-free fetal DNA technique.

Considering the best model for developing countries, several aspects must be taken into account: feasibility, expertise requirement, simplicity, costs of screening tests and invasive diagnosis, capacity in chromosome lab development etc. Note that this study did not include integrated tests, because of the high costs of double screenings with small additional detection rate. It also excluded NT and genetic sonogram, because of the need for high expertise, not practical for extensive use in low resource settings. FTS alone was not suitable since many women had their first visit in late gestation. C-S plus STS was most effective but had higher costs due to the high rate of intermediate risk requiring STS and was complicated by counseling as well as anxiety during waiting for the final risk. Therefore I-S seems to be more attractive, though with slightly lower detection rate.


The strengths of this study are as follows: 1) It is a prospective large-scale population-based study. 2) All models were based on feasibility and simplicity. 3) All newborns, either high risk or low risk determined by MSS, were evaluated for DS by pediatricians in the project. 4) All samples were properly collected and transported and run at the same laboratories. We were conscious of the logistics and temperature, which have been proven to have an obvious influence on the serum marker levels, as suggested by our preliminary study [20]. 5) The high homogeneity of the participants (Thai ethnicity). 6) This project was undertaken under the support of a non-profit organization without conflict of interest.


The weaknesses of this study are as follows: 1) Some other well-known strategies like integrated screening or fully combined first trimester screening were not included; however, such strategies are not suitable for low resource settings. 2) Trisomy13 and 18 were not taken into account since they were not a major problem in developing countries and were considered incompatible with life. 3) The uptake rate of MSS in this study could not represent the real practice since all women in this project were offered the MSS free of charge. 4) The dataset originally used for categorization based on CRR could not be exactly the same as that based on TRR since the cases categorized as low risk and high risk by CRR in the first trimester did not contribute data for the second trimester screening, whereas the intermediate risk women did. In principle, if they were firstly categorized using TRR, those women might have become intermediate risk with contributing data for second trimester screening. 5) The models in this study were primarily focused on our national health care. Thus, the results might not be perfectly accurate for other countries’ strategies. However, we believe that this could probably be a model for several developing countries especially many parts of Asia.


MSS reference ranges derived from Caucasian pregnant women could not be effectively used with Southeast Asian women even with the use of racial factor correction. This is because the false positive rate is far too high. While the detection rate is comparable, the rate of amniocentesis (false positive) is high, leading to an increased burden of amniocentesis and chromosome laboratories as well as high fetal loss rate secondary to the procedure. Each geographical area should have its own reference ranges for its own population.

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author upon reasonable request.





cost-benefit analysis


Caucasian reference ranges


contingent first trimester screening


Down syndrome screening


false positive rate


First trimester screening


human chorionic gonadotropin


High risk


independent first and second trimester screening


Low risk


Maternal serum screening


non-invasive prenatal test


Nuchal translucency


Pregnancy-associated plasma protein A


Second trimester screening


Thai reference range


unconjugated estriol


  1. 1.

    Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the serum, urine and ultrasound screening study (SURUSS). J Med Screen. 2003;10(2):56–104.

    CAS  PubMed  Google Scholar 

  2. 2.

    Ardawi MS, Nasrat HA, Rouzi AA, Qari MH, Al-Qahtani MH, Abuzenadah AM. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-a and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women. PrenatDiagn. 2007;27(4):303–11.

    Google Scholar 

  3. 3.

    Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-a: impact of maternal and pregnancy characteristics. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2008;31(5):493–502.

    CAS  Article  Google Scholar 

  4. 4.

    Leung TY, Spencer K, Leung TN, Fung TY, Lau TK. Higher median levels of free beta-hCG and PAPP-A in the first trimester of pregnancy in a Chinese ethnic group. Implication for first trimester combined screening for Down's syndrome in the Chinese population. Fetal DiagnTher. 2006;21(1):140–3.

    Article  Google Scholar 

  5. 5.

    Shohat M, Frimer H, Shohat-Levy V, Esmailzadeh H, Appelman Z, Ben-Neriah Z, et al. Prenatal diagnosis of Down syndrome: ten year experience in the Israeli population. AmJ Med GenetA. 2003;122A(3):215–22.

    Article  Google Scholar 

  6. 6.

    Spencer K, Bindra R, Nicolaides KH. Maternal weight correction of maternal serum PAPP-A and free beta-hCG MoM when screening for trisomy 21 in the first trimester of pregnancy. PrenatDiagn. 2003;23(10):851–5.

    Google Scholar 

  7. 7.

    Bryant-Greenwood PK, O'Brien JE, Huang X, Yaron Y, Ayoub M, Johnson MP, et al. Maternal weight differences do not explain ethnic differences in biochemical screening. Fetal DiagnTher. 1998;13(1):46–8.

    CAS  Article  Google Scholar 

  8. 8.

    Lee JH, Park Y, Suh B, Song SM, Kwon OH, Kim JH. Performance characteristics of the UniCel DxI 800 immunoassay for the maternal serum quadruple test, including median values for each week of gestation, in Korean women. Korean J Lab Med. 2010;30(2):126–32.

    CAS  Article  Google Scholar 

  9. 9.

    Wang YY, Luo J, Zhu MW, Liu LN, Ma X. Second-trimester double or triple screening for Down syndrome: a comparison of Chinese and Caucasian populations. IntJ GynaecolObstet. 2006;94(1):67–72.

    Google Scholar 

  10. 10.

    Brooks K, Chik L, O'Brien JE, Ayoub M, Johnson MP, Evans MI. Variability of adjustments to indices in determining patient risk in biochemical screening. Fetal DiagnTher. 1999;14(1):41–6.

    CAS  Article  Google Scholar 

  11. 11.

    O'Brien JE, Dvorin E, Drugan A, Johnson MP, Yaron Y, Evans MI. Race-ethnicity-specific variation in multiple-marker biochemical screening: alpha-fetoprotein, hCG, and estriol. Obstet Gynecol. 1997;89(3):355–8.

    CAS  Article  Google Scholar 

  12. 12.

    Watt HC, Wald NJ, Smith D, Kennard A, Densem J. Effect of allowing for ethnic group in prenatal screening for Down's syndrome. PrenatDiagn. 1996;16(8):691–8.

    CAS  Google Scholar 

  13. 13.

    Lamlertkittikul S, Chandeying V. Experience on triple markers serum screening for Down's syndrome fetus in Hat Yai, regional hospital. J Med AssocThai. 2007;90(10):1970–6.

    Google Scholar 

  14. 14.

    Luewan S, Sirichotiyakul S, Yanase Y, Traisrisilp K, Tongsong T. Median levels of serum biomarkers of fetal Down syndrome detected during the first trimester among pregnant Thai women. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2012;117(2):140–3.

    CAS  Article  Google Scholar 

  15. 15.

    Wanapirak C, Sirichotiyakul S, Luewan S, Yanase Y, Traisrisilp K, Tongsong T. Different median levels of serum triple markers in the second trimester of pregnancy in a Thai ethnic group. J Obstet Gynaecol Res. 2012;38(4):686–91.

    Article  Google Scholar 

  16. 16.

    Burton BK, Prins GS, Verp MS. A prospective trial of prenatal screening for Down syndrome by means of maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol. AmJObstetGynecol. 1993;169(3):526–30.

    CAS  Google Scholar 

  17. 17.

    Cheng EY, Luthy DA, Zebelman AM, Williams MA, Lieppman RE, Hickok DE. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol. ObstetGynecol. 1993;81(1):72–7.

    CAS  Google Scholar 

  18. 18.

    Haddow JE, Palomaki GE, Knight GJ, Williams J, Pulkkinen A, Canick JA, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. NEnglJ Med. 1992;327(9):588–93.

    CAS  Article  Google Scholar 

  19. 19.

    Wenstrom KD, Williamson RA, Grant SS, Hudson JD, Getchell JP. Evaluation of multiple-marker screening for Down syndrome in a statewide population. AmJObstetGynecol. 1993;169(4):793–7.

    CAS  Google Scholar 

  20. 20.

    Sirichotiyakul S, Luewan S, Sekararith R, Tongsong T. False positive rate of serum markers for Down syndrome screening: does transportation have any effect. J Med Assoc Thail. 2012;95(2):152–5.

    Google Scholar 

Download references


The authors wish to thank the Research Fund, Chiang Mai University for financial support.


Chiang Mai University Research Fund (CMU-2562). The funder had no any role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Author information




CW: contributed to the conception, design of the research and administration of the project, and drafting/revising the manuscript; SS: contributed to the conception, acquisition of data and administration of the project, and revising the manuscript; WP: contributed to acquisition of data, and revising the manuscript; FT: contributed to acquisition of data, and revising the manuscript; KS: contributed to acquisition of data, and revising the manuscript; SL: contributed to acquisition of data, drafting and revising the manuscript; KT: contributed to acquisition of data, and revising the manuscript; PJ: contributed to acquisition of data, and revising the manuscript; TT: contributed to the conception, design of the research, analysis or interpretation and drafting/revising the manuscript. All authors contributed to the interpretation and writing of the paper and approved the final version.

Corresponding author

Correspondence to Theera Tongsong.

Ethics declarations

Ethics approval and consent to participate

This study received ethnical approval from the institute review boards of Faculty of Medicine, Chiang Mai University (Ethics Committee 4; Research ID 4981).

All participants signed Informed Consent Forms.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wanapirak, C., Piyamongkol, W., Sirichotiyakul, S. et al. Fetal Down syndrome screening models for developing countries; Part I: Performance of Maternal Serum Screening. BMC Health Serv Res 19, 897 (2019).

Download citation


  • Down syndrome
  • Prenatal screening
  • Prenatal diagnosis
  • Cost-benefit
  • Developing country